Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 12M | 40% |
| Net Income | -10M | 42.9% |
| EBITDA | -12M | 40% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 137M | 6% |
| Total Liabilities | 7.2M | 0.9% |
| Total Equity | 130M | 6.4% |
| Shares Outstanding | 32M | 0% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -9.1M | 37.4% |
| Cash from investing | -13M | 489.4% |
| Cash from financing | 1,000 | 0% |
EPS
Financial Highlights for Sagimet Biosciences in Q2 '25
Operating Expenses for this period were 12M, showing a -40% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -10M, showing a 42.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -12M, showing a 40% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
